Most Read Articles
Jairia Dela Cruz, 15 Apr 2019
Use of oral contraceptives (OC) confers some protection against bone loss in patients with anorexia nervosa (AN), a study has found. Areal bone mineral density preservation improves with longer durations of OC use and shorter delays between disease onset and OC initiation, and appears to be most pronounced in patients more severe forms of AN.
17 Oct 2019
Use of direct acting antivirals (DAAs) to treat hepatitis C virus (HCV) infection is feasible during pregnancy, as these drugs are highly effective and treatment duration is relatively short, according to a study. In addition, DAA treatment helps improve maternal health and prevent vertical transmission.
Rachel Soon, 16 Nov 2019

The third Pharmaceutical Industry Pharmacists Insight (PIPI 3.0) symposium will highlight areas of the pharmaceutical industry often overlooked by those entering the pharmacy profession.

Pearl Toh, 17 Apr 2019
A contraceptive vaginal system (Annovera) releasing a combination of segesterone acetate and ethinyl estradiol (SA/EE) effectively inhibits ovulation up to a year even at low systemic levels of SA, reports a review study presented at ENDO 2019.

5-AZA effective for myelodysplastic syndromes in elderly adults

15 Jan 2020

In elderly adults with intermediate- or high-risk myelodysplastic syndromes (MDS) or oligoblastic acute myeloid leukaemia (AML), 5-azacytidine (5-AZA) may be an effective treatment option, a recent study has found.

Researchers conducted a retrospective analysis of 102 elderly adults (median age, 83 years) who had intermediate-2 or high-risk MDS. Frontline treatment was carried out with a single dose of 75 mg/m2/day of 5-AZA, given for seven consecutive days. The study outcomes were treatment response, overall survival and time to transformation to AML.

The overall response rate was 44.3 percent, with a median response duration of 12 months. Sixty-three participants had available data for 5-AZA relative dose intensity (RDI); of these, 81.0 percent (n=63) were able to take the standard dose. Almost half (24 of 52; 46.2 percent) of patients who were dependent at baseline achieved transfusion independence.

Over a median follow-up of 17 months, the median AML-free survival time was estimated to be 49 months. This turned out to be longer in participants who had responded to the treatment (failure vs overall response: hazard ratio [HR], 7.56, 95 percent confidence interval [CI], 2.61–21.95; p<0.001). 5-AZA RDI did not significantly affect AML-free survival (p=0.51).

On the other hand, the medial overall survival estimate was 17 months, similarly greater in those who responded to 5-AZA treatment (failure vs overall response: HR, 6.00, 95 percent CI, 3.07–11.70; p<0.001). RDI was not significantly predictive of overall survival.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 15 Apr 2019
Use of oral contraceptives (OC) confers some protection against bone loss in patients with anorexia nervosa (AN), a study has found. Areal bone mineral density preservation improves with longer durations of OC use and shorter delays between disease onset and OC initiation, and appears to be most pronounced in patients more severe forms of AN.
17 Oct 2019
Use of direct acting antivirals (DAAs) to treat hepatitis C virus (HCV) infection is feasible during pregnancy, as these drugs are highly effective and treatment duration is relatively short, according to a study. In addition, DAA treatment helps improve maternal health and prevent vertical transmission.
Rachel Soon, 16 Nov 2019

The third Pharmaceutical Industry Pharmacists Insight (PIPI 3.0) symposium will highlight areas of the pharmaceutical industry often overlooked by those entering the pharmacy profession.

Pearl Toh, 17 Apr 2019
A contraceptive vaginal system (Annovera) releasing a combination of segesterone acetate and ethinyl estradiol (SA/EE) effectively inhibits ovulation up to a year even at low systemic levels of SA, reports a review study presented at ENDO 2019.